Advertisement
Advertisement


News

Prezcobix, New Once-Daily HIV Drug, Approved by FDA

January 30, 2015

On Jan. 29, Prezcobix, a once-daily combination drug, was approved by the U.S. Food and Drug Administration (FDA), for the treatment of HIV in adults.

The new drug contains 800 mg of the protease inhibitor darunavir (Prezista) and 150 mg of the pharmacokinetic booster cobicistat (Tybost). Prezcobix is recommended to be taken once a day with food, and in conjunction with other antiretroviral agents.

Prezcobix was the second cobicistat-containing drug approved by the FDA on Jan. 29, shortly after the approval of Evotaz.

Advertisement
Previous studies showed that the safety and efficacy of darunavir boosted with cobicistat were comparable to that of darunavir boosted with ritonavir, according to the FDA press release.

Moreover, a study from ICAAC 2014 found that cobicistat was well-tolerated by HIV-positive patients with mild to moderate renal impairment who made the switch from ritonavir as a booster.

The approval of Prezcobix may help patients reduce the number of pills in their regimen, potentially relieving pill burden and increasing adherence.

Treatment-experienced patients should have resistance testing done before being prescribed Prezcobix, the FDA states.

Prezcobix is manufactured by the pharmaceutical company Janssen Pharmaceuticals.

Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.

Follow Warren on Twitter: @WarrenAtTheBody.


Copyright © 2015 Remedy Health Media, LLC. All rights reserved.




This article was provided by TheBodyPRO.com.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.